BridgeBio Pharma Price to Sales Ratio 2018-2023 | BBIO
Historical PS ratio values for BridgeBio Pharma (BBIO) over the last 10 years. The current P/S ratio for BridgeBio Pharma as of April 26, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| BridgeBio Pharma P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2024-04-26 |
24.88 |
|
429.30 |
| 2023-12-31 |
40.37 |
$0.06 |
696.58 |
| 2023-09-30 |
26.37 |
$0.06 |
440.12 |
| 2023-06-30 |
17.20 |
$0.04 |
463.00 |
| 2023-03-31 |
16.58 |
$0.53 |
31.30 |
| 2022-12-31 |
7.62 |
$0.53 |
14.40 |
| 2022-09-30 |
9.94 |
$0.61 |
16.40 |
| 2022-06-30 |
9.08 |
$0.62 |
14.65 |
| 2022-03-31 |
10.15 |
$0.48 |
20.93 |
| 2021-12-31 |
16.68 |
$0.48 |
34.99 |
| 2021-09-30 |
46.87 |
$0.39 |
120.65 |
| 2021-06-30 |
60.96 |
$0.44 |
138.15 |
| 2021-03-31 |
61.60 |
$0.07 |
842.20 |
| 2020-12-31 |
71.11 |
$0.07 |
1018.64 |
| 2020-09-30 |
37.52 |
$0.20 |
187.36 |
| 2020-06-30 |
32.61 |
$0.13 |
248.01 |
| 2020-03-31 |
29.00 |
$0.36 |
80.58 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.278B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
